Page results
-
This page is for parents, carers and relatives whose child is having radiotherapy treatment to a part of the brain. This page breaks down the side effects your child may experience during and after treatment, and how best to cope with them.
-
This page has been written for patients who wish to find out more about a new procedure for epilepsy that does not involve removing parts of brain, known as EASEE® (Epicranial Application of Stimulation Electrodes for Epilepsy)
-
UCLH is one of the largest blood cancers treatment centres in Europe, with both inpatient beds and a comprehensive day care service. The service is the main treatment centre for patients from north and east London, and west Essex.
-
This page is for parents and carers whose child is having radiotherapy treatment to the chest, or mediastinum.
-
A surgical operation normally carried out to correct a blocked nasal passage may help patients who lost their sense of smell after contracting a COVID-19 infection, according to new research from UCLH.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the abdomen and pelvis.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the testes.
-
The world’s largest-ever clinical trial of treatments to slow or stop the progression of Parkinson’s disease has launched at UCLH,
-
A technique to improve the precision of prostate cancer surgery means that almost twice as many men preserve their erectile function compared to those undergoing standard surgery, according to results from a clinical trial led by researchers from UCL and UCLH.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the whole brain.
File results
-
FOI/2023/0301 - Meat served at the Trust that may contain nitrates or nitrites
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0326 - Risk management system reporting rates for adverse events
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2019/77 Discharge and readmittance for patients with no fixed abode
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide